ETHIZIA Hemostatic Patch
ETHICON, Inc. · Decision date Feb 26, 2026
What did the FDA decide?
FDA records P240035/S005 as a supplement to PMA P240035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 26, 2026.
FDA approval order statement
additional supplier for temperature controlled storage and transport
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Feb 26, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240035/S005
- Regulatory pathway
- PMA supplement
- Applicant
- ETHICON, Inc.
- Product code
- SGV
- Decision code
- OK30
- Decision date
- Feb 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen with polymeric additives.
- Applicant
- ETHICON, Inc.
- Product code
- SGV
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240035 · Original PMA
ETHIZIA
P240035/S001 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S003 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S005 received
Application receipt date recorded by FDA.
P240035/S006 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S005 · FDA decision
30-Day Notice
P240035/S002 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S004 · Related supplement
ETHIZIA Hemostatic Patch
Timeline entries are records held by MedtechLedger for P240035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ETHIZIAP240035 | ETHICON, Inc. | PMA approval | Dec 15, 2025 | FDA |
ETHIZIA Hemostatic PatchP240035/S001 | ETHICON, Inc. | PMA supplement | Jan 22, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S003 | ETHICON, Inc. | PMA supplement | Jan 28, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S006 | ETHICON, Inc. | PMA supplement | Feb 24, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S002 | ETHICON, Inc. | PMA supplement | Jun 25, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S004 | ETHICON, Inc. | PMA supplement | Aug 27, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ETHICON, Inc.
- Headquarters
- Not reported
- Brand website
- ethicon.com
- FDA applicant address
- 1000 Rte. 202, Raritan, NJ, 08869
Sources and methodology
- Original FDA record: P240035/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
